Physician profile
Neil Sharma
NPI 1801081807
$405,257.68
in general payments reported to CMS, 2019-2025
25 companies · $95K in 2025
The $95K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $16K · 2021: $20K · 2022: $52K · 2023: $47K · 2024: $120K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $137K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Travel and Lodging: $33K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $137,242.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,137.50 |
| Travel and Lodging | $32,800.28 |
| Food and Beverage | $10,003.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $267,354.17 | 2019-2025 | Resolution 360 Clip, General - Therapies, Exalt Model D |
| Olympus Corporation | $50,052.18 | 2024-2025 | Gastrointestinal Videoscope, Evis Exera II Ultrasound Gastrovideoscope, Evis Exera III Colonovideoscope |
| US Endoscopy | $31,900.00 | 2020-2025 | |
| Olympus Corporation of The Americas | $23,682.71 | 2021-2025 | Evis Exera III Colonovideoscope, Evis Exera Lll Colonovideoscope, Single Use Aspiration Needle Na-U200h |
| Medtronic, INC. | $12,522.10 | 2021-2025 | Nexpowder, Sharkcore, Prodigi |
| Covidien Lp | $4,922.19 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $3,818.63 | 2019-2025 | |
| Fujifilm Healthcare Americas Corporation | $3,578.65 | 2023-2025 | Fujifilm |
| Erbe USA INC | $2,023.05 | 2021-2025 | Erbevio3, Vio3, Vio3 Hybrid Knife |
| Olympus Medical Systems Corporation | $1,925.00 | 2024-2025 | |
| Conmed Corporation | $1,535.61 | 2021-2023 | Beamer System |
| Creo Medical INC. | $743.80 | 2021-2023 | Speedboat |
| Steris Corporation | $584.70 | 2024-2025 | |
| Cook Medical LLC | $115.90 | 2019 | |
| Merck Sharp & Dohme LLC | $104.89 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $83.20 | 2019 | |
| Abbvie INC. | $79.97 | 2019-2025 | Skyrizi |
| Pentax of America, INC. | $66.40 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $53.02 | 2022 | |
| Eisai INC. | $45.27 | 2019 | |
| Omega Medical Imaging, LLC | $21.45 | 2022 | |
| Shionogi INC | $16.38 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.28 | 2021 | |
| Lilly USA, LLC | $14.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.